Ganovsky Matthew

Co-Founder Matthew Ganovsky sells 75,800 ABL shares at $8.00; stock now $7.80, down 37.4% from 52-week high.

Matthew Ganovsky, Co-Founder and President of Abacus Life, sold 75,800 shares at $8.00 on 2024-12-20, reducing his position from 10.09M to 10.01M shares, a -0.8% reduction in holdings. The transaction occurred 30 days after a prior sell at the same ticker (2024-11-21), continuing a pattern of recent dispositions. The current price of $7.80 reflects a 37.4% decline from the 52-week high of $12.47, though the stock has recovered 3.3% over the past 30 days and sits near its 52-week low. The company reports a net loss of $5.1M on $28.1M in quarterly revenue, with a P/E of 45.88 and revenue growth of 48.5% year-over-year. The timing of consecutive sell transactions during a material drawdown warrants attention to whether they reflect operational cash needs or a reassessment of near-term business prospects.

Co-founder Matthew Ganovsky sells 156,250 ABL shares at $8.00; stock now trading 38.5% below 52-week high amid rising losses.

Matthew Ganovsky, Co-Founder and President, sold 156,250 shares (1.4% of pre-transaction holdings) at $8.00 on 2024-11-21, reducing his stake from 11,003,297 shares to 10,847,047 shares. The sale occurred at a significant premium to the current price of $7.67, and notably the stock has fallen 38.5% from its 52-week high of $12.47, with a 25.8% decline over the past 90 days. The timing of the sale warrants attention given the company's recent financial deterioration: while annual revenue growth stands at 48.5%, the latest quarter shows net losses of $-5,125,055.00 against quarterly revenue of $28,148,491.00, indicating profitability challenges despite top-line growth. As a co-founder with substantial remaining holdings (10.85M shares), the sale represents a modest liquidation, but in the context of elevated net losses and significant share price depreciation from the year's highs, it invites examination into the seller's views on near-term prospects.